3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Active not recruiting
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
2
Non Small Cell Lung Cancer NSCLC
1
Lung Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
pembrolizumab
45
Carboplatin
40
Cisplatin
36
Paclitaxel
29
Pemetrexed
24
Nivolumab
24
Gemcitabine
23
Dexamethasone
21
Rituximab
18
Ipilimumab
16
Cyclophosphamide
15
Fluorouracil
14
Capecitabine
14
atezolizumab
13
Docetaxel
13
trastuzumab deruxtecan
12
durvalumab
12
Trastuzumab
12
Lenalidomide
12
daratumumab
11
Cytarabine
11
olaparib
10
Prednisone
10
Bortezomib
10
Bevacizumab
10
130-nm albumin-bound paclitaxel
10
Doxorubicin
9
venetoclax
8
Oxaliplatin
8
Crizotinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Interventional
×
Has announcements
×
tremelimumab
×
Clear all
NCT03043872
2026-04-22
CASPIAN
AstraZeneca
Phase 3
Active not recruiting
987 enrolled
42 charts
1 FDA
NCT03298451
2026-03-20
HIMALAYA
AstraZeneca
Phase 3
Active not recruiting
1,324 enrolled
31 charts
1 FDA
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA
NCT03703297
2025-11-21
ADRIATIC
AstraZeneca
Phase 3
Active not recruiting
730 enrolled
19 charts
1 FDA